Abpro's Cancer Tumor Therapy Receives FDA Clearance

Abpro Holdings, a biotechnology company, has announced that its investigational new drug application for its solid cancer tumor therapy, ABP-102, has received clearance from the US FDA. ABP-102 is designed to redirect a patient's immune system to fight cancer by co-targeting HER2 and CD3. The company is focused on developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.